Avenue Therapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
OID
Fortress Biotech, a 10% owner and director, increased its beneficial ownership in Avenue Therapeutics by 111,209 shares of common stock as an annual dividend.
OID
Fortress Biotech, a 10% owner of Avenue Therapeutics, acquired 33,724 shares of common stock as an equity fee following Avenue Therapeutics' receipt of proceeds from warrant exercises.
OID
Avenue Therapeutics director Neil Herskowitz sold 23 shares of common stock at $2.97 per share on December 2, 2024.
OID
Director Jay D. Kranzler of Avenue Therapeutics, Inc. (ATXI) sold 61 shares of common stock at $2.24 per share on November 5, 2024.
OID
Director Jay D Kranzler increased his holdings in Avenue Therapeutics through open market purchases of common stock.
OID
Director Lindsay A. Rosenwald acquired 30,000 employee stock options in Avenue Therapeutics, Inc. on September 23, 2024.
OID
Director Neil Herskowitz acquired 30,000 employee stock options in Avenue Therapeutics, Inc.
OID
Director Curtis Gale Oltmans acquired 30,000 employee stock options in Avenue Therapeutics, Inc. on September 23, 2024.
OID
A Form 4 filing reveals that Avenue Therapeutics CEO Alexandra MacLean was granted 170,000 restricted stock units.
OID
Director Jay D. Kranzler reports acquisition of 30,000 employee stock options in Avenue Therapeutics, Inc.
OID
David Jin, Interim PFO and COO of Avenue Therapeutics, reports the acquisition of 65,000 shares of common stock through restricted stock units.
OID
Director Faith L. Charles acquired 30,000 employee stock options in Avenue Therapeutics, Inc. on September 23, 2024.
OID
Fortress Biotech, a 10% owner of Avenue Therapeutics, acquired 413,507 shares of common stock as an equity fee following the closing of an equity financing.